NCI has selected Exact Sciences Corp.’s testing laboratory in Phoenix, AZ to participate in the ComboMATCH clinical trials, an NCI-funded precision medicine initiative. As a ComboMATCH-designated lab, Exact Sciences will use its new OncoExTra test to analyze tumor tissue and paired normal blood samples from patient participants and uncover the specific abnormalities in a patient’s tumor that may be most effective to treat.
What should a cancer center look like in an era of AI, genomics, complex patient populations, rising costs, and declining public trust in science?
